Issues - Gennaio 2025

Jhaveri KL, Neven P, Casalnuovo ML, et al.

Imlunestrant with or without abemaciclib in advanced breast cancer

N Engl J Med 2024 Dec 11. Epub ahead of print

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract | Scarica ppt

---

Kalinsky K, Bianchini G, Hamilton E, et al.

Abemaciclib plus fulvestrant in advanced breast cancer following progression on CDK4/6 inhibition: results from the phase III postMONARCH trial

J Clin Oncol 2024 Dec 18:JCO2402086. Epub ahead of print

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract | Scarica ppt

---

Sonke GS, van Ommen-Nijhof A, Wortelboer N, et al.

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer

Nature 2024;636(8042):474-480

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract | Scarica ppt

---

Reimer T, Stachs A, Veselinovic K, et al.

Axillary surgery in breast cancer – Primary results of the INSEMA trial

N Engl J Med 2024 Dec 12. Epub ahead of print

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract | Scarica ppt

---

Pusztai L, Hoag JR, Albain KS, et al.

Development and validation of the RSClinN+ tool to predict prognosis and chemotherapy benefit for hormone receptor-positive, node-positive breast cancer

J Clin Oncol 2024 Dec 2:JCO2401507. Epub ahead of print

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract | Scarica ppt

---

Chen XC, Jiao DC, Qiao JH, et al.

De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial

Lancet Oncol 2024 Nov 26:S1470-2045(24)00581-3

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract

---

Han HS, Aldrich AL, Garg SK, et al.

Alteration of the tumor microenvironment with intratumoral dendritic cells before chemotherapy in ERBB2 breast cancer: a nonrandomized clinical trial

JAMA Oncol 2024 Dec 5:e245371. Epub ahead of print

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract

---

Palmér S, Valachis A, Lindman H, et al.

Omission of postoperative radiotherapy after breast-conserving surgery in low-risk breast cancer

J Natl Cancer Inst 2024 Dec 4:djae315

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract

---

Bargon CA, Mink Van Der Molen DR, Young-Afat DA, et al.

Clinical and patient-reported outcomes after oncoplastic versus conventional breast conserving surgery-a longitudinal, multicenter cohort study

J Natl Cancer Inst 2024 Nov 29:djae310

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract

---

Milano M, Valenza C, Ferrari A, et al.

Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer

Eur J Cancer 2024 Dec 6;215:115164. Epub ahead of print

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract

---

Partridge AH, Hyslop T, Rosenberg SM, et al.

Patient-reported outcomes for low-risk ductal carcinoma in situ: a secondary analysis of the COMET randomized clinical trial

JAMA Oncol 2024 Dec 12. Epub ahead of print

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract

---

Meattini I, De Santis MC, Visani L, et al.

Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial

Lancet Oncol 2024 Dec 11:S1470-2045(24)00661-2

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract

---

Chen L, Li H, Zhang H, et al.

Camrelizumab vs placebo in combination with chemotherapy as neoadjuvant treatment in patients with early or locally advanced triple-negative breast cancer: the CamRelief randomized clinical trial

JAMA 2024 Dec 13. Epub ahead of print

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract

---

Ho AY, Shiao S, Kobald SA, et al.

PEARL: a phase ib/ii biomarker study of adding radiation therapy to pembrolizumab before neoadjuvant chemotherapy in human epidermal growth factor receptor 2-negative breast cancer

J Clin Oncol 2024;42(36):4282-4293

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract

---

Dennis N, Dunton K, Livings C, et al.

Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial

Eur J Cancer 2024; Volume 0, Issue 0, 115192. Epub ahead of print

Simonpietro Marrocco Gennaio 2025, Issues

Leggi abstract

---